Health Tech Capitol | Madison Vaccines expands clinical trial for prostate cancer treatment
16030
post-template-default,single,single-post,postid-16030,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Madison Vaccines expands clinical trial for prostate cancer treatment

05 Aug Madison Vaccines expands clinical trial for prostate cancer treatment

Posted at 13:04h in Uncategorized by
0 Likes

A Madison drug development company says it is expanding a study of one of its prostate cancer drug prospects as a result of upbeat early results.

Madison Vaccines Inc. (MVI) said that after a small, early study of its potential prostate cancer treatment, MVI-816, it has enrolled 20 more patients in the study, who will be treated for up to 48 weeks.

The clinical trial involves using MVI-816 along with Merck’s Keytruda in patients with advanced prostate cancer.

Read more at the Wisconsin State Journal

No Comments

Sorry, the comment form is closed at this time.